SynthesisScientific reports2026
Health-related quality of life in patients with cervical cancer: a systematic review and meta-analysis of EQ‑5D utility scores.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer substantially impairs HRQoL, particularly among women in socially and economically productive age groups. EQ-5D utility values are important inputs for quality-adjusted life-year estimation, cost-utility analysis, and health technology assessment; however, pooled EQ-5D estimates for cervical cancer remain limited. This PRISMA 2020-compliant systematic review and meta-analysis searched PubMed, Embase, Scopus, and the Cochrane Library from inception to July 2025. The protocol was registered in PROSPERO (CRD420251077051). Eligible studies included adults with cervical cancer reporting EQ-5D-3 L, EQ-5D-5 L, EQ-5D VAS, or EQ-5D domain-level outcomes. Random-effects meta-analysis was used to estimate pooled mean utility and VAS scores. Heterogeneity, publication bias, sensitivity analyses, subgroup analyses, prediction intervals, and meta-regression were assessed. Twenty-four studies including 281,958 participants from 15 countries were included. Seventeen studies contributed to the EQ-5D utility meta-analysis, yielding a pooled mean utility score of 0.79 (95% CI: 0.73-0.85; 95% prediction interval: 0.52-1.05; I² = 99.6%). Seventeen studies reported EQ-5D VAS scores, with a pooled mean of 71.82 (95% CI: 67.95-75.69; 95% prediction interval: 54.54-89.11; I² = 98.3%). Stage-specific estimates were inconsistent, particularly for Stage IV disease, and should be interpreted cautiously because of small sample size, potential survivor bias, and high between-study variability. Pain/discomfort and anxiety/depression were the most frequently affected EQ-5D domains. Cervical cancer is associated with reduced HRQoL. The pooled EQ-5D estimates provide useful reference values for economic evaluations and HTA, but substantial heterogeneity and wide prediction intervals indicate that local adaptation and cautious interpretation are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.